Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, is excited about the new Eliminate Hepatitis C (HCV) program put forth by the Biden Administration and being led by former NIH Director Francis Collins, MD, PhD, who is serving as a scientific advisor to the Biden Administration. “This is something we have been asking for years…We know we can end hepatitis C,” Schmid stated.
Carl Schmid and Kevin Herwig present HIV + Hepatitis Policy Institute’s study modeling how much funding is required for a national PrEP program to reduce disparities, cover medications and ancillary services such as clinic visits and laboratory testing for the uninsured, and to increase outreach and adherence services.
NAIC Consumer Representative Carl Schmid speaks at the 2023 NAIC Spring Meeting on a panel about how insurers create barriers to prescription drugs through onerous prior-authorization requirements.
Carl Schmid speaks with “Houston Matters” radio, along with a San Antonio, Texas PrEP client, about private insurers continuing to charge cost-sharing for PrEP and associated services and its impact on PrEP uptake.
Carl Schmid discusses discrimination in prescription drug formularies, demonstrating how some PBMs and private insurers violate ACA provisions and hurt patients by placing life-saving prescription drugs on higher cost tiers.